info@marketresearchleaks.com

--

Her Helping Habit Expands Its Mission to Transform Family-Building Through Ethical, Transparent, and Relationship-Centered Fertility Support

Her Helping Habit (HHH), a pioneering leader in known egg donation, surrogacy coordination, and holistic fertility consulting, is proud to announce a renewed expansion of its mission and services—continuing its commitment to rewriting the narrative of infertility support worldwide. Founded in 2018, Her Helping Habit has grown from a small, purpose-driven initiative into a trusted global resource, helping intended parents, donors, and surrogates build families through compassion, connection, and ethical excellence. Canada, 13th Dec 2025 — Her Helping Habit (HHH), a pioneering leader in known egg donation, surrogacy coordination, and holistic fertility consulting, is proud to announce a renewed expansion of its mission and services—continuing its commitment to rewriting the narrative of infertility support worldwide. Founded in 2018, Her Helping Habit has grown from a small, purpose-driven initiative into a trusted global resource, helping intended parents, donors, and surrogates build families through compassion, connection, and ethical excellence. More information can be found at https://www.herhelpinghabit.com. With a vision rooted in transparency and a belief that family-building should honour every participant, Her Helping Habit stands apart for its focus on known donation—a transformative model that prioritizes relationship-building, informed consent, emotional well-being, and long-term family connection.“At its core, Her Helping Habit is about supporting people through one of the most emotional, personal, and life-changing journeys they will ever walk,” says Katie, Founder and Surrogacy Program Manager. “We understand the vulnerability required to ask for help and the profound courage behind every decision to become a parent, donor, or surrogate. Our mission is to guide each client with honesty, respect, trauma-sensitive support, and unwavering transparency.”Backed by a team of experienced donors and surrogates—including Sarah, Egg Donor Program Manager, and Emily, Embryo Donor Program Manager—HHH continues to expand its reach across Canada and worldwide through virtual services and personalized fertility pathways. A New Era of Known Donation: Transforming Lives Through Authentic RelationshipsHer Helping Habit is at the forefront of a movement that challenges long-standing norms in the fertility world. While anonymous gamete donation has long been the default option, HHH envisions a future where anonymity becomes a thing of the past—replaced with deeper relationships, clarity, and empowerment for every person involved.Known donation offers families the opportunity to:Understand their donor’s story, personality, and values Honour the emotional identity and future curiosity of donor-conceived children Build long-term, meaningful connections that feel natural and supportiveFor donors, known donation provides a sense of purpose, transparency, autonomy, and reassurance that their gift will forever be appreciated within a relationship of shared understanding.This relationship-centered approach has led to countless heartfelt stories. “Having a known donor is more than just having an egg provider,” share Peng & Shuwen, intended parents in Toronto. “We developed a deep, genuine relationship with our donor that far exceeded anything we imagined when starting this journey. It made the entire experience so much more meaningful.”Holistic, Trauma-Informed Support for Every Step of the JourneyHer Helping Habit stands firmly on a holistic foundation that recognizes the physical, emotional, and psychological complexities of infertility and family-building. Whether working with intended parents, surrogates, donors, or individuals seeking counselling, the HHH team approaches each case with therapeutic insight, empathy, and specialized training.From the first consultation, clients receive support that extends well beyond logistical coordination. Services include:Egg donation & surrogacy matching Embryo adoption support Fertility consulting and education Individual counselling and trauma-informed guidance Personalized program selection Support for designing a custom family-building pathway Clients attest to the impact of HHH’s compassionate, highly responsive approach.“Katie is one of a kind,” says Nancy, a fertility consulting and counselling client. “I never realized how deeply this would affect my life until working with her. She supported me through every struggle with empathy, education, and unwavering guidance.”A Process Built on Clarity and ConfidenceHHH’s signature 3-step pathway ensures clients feel informed, supported, and grounded from start to finish.Step 1 — Connect with the HHH TeamClients meet with an HHH Coordinator to explore their goals—whether becoming a parent, becoming a donor or surrogate, or seeking education, advocacy, or emotional support.Step 2 — Share Their StoryClients complete a personal questionnaire to help HHH understand their needs and choose the program that aligns with them.Step 3 — Begin Their JourneyWith a dedicated coordinator guiding each step, clients move forward with a plan designed specifically for their emotional, physical, and personal circumstances.Human Stories at the Heart of HHH’s MissionThe impact of Her Helping Habit is reflected in countless testimonials from families and donors across Canada:Intended parents from Vancouver praise the team’s quick communication, kindness, and total devotion to their journey.Egg donors like Samantha and Jordan credit HHH for providing transparent medical information, detailed risk education, and constant emotional support. Surrogates and donors working with HHH often build lifelong friendships with intended parents. Single parents by choice, like Amy in Montreal, share that HHH gave them the confidence and guidance needed to pursue motherhood on their terms. “Her Helping Habit staff were understanding and quick to answer our questions,” says one Vancouver couple. “Katie puts her whole heart into helping. Her passion is inspiring.”CHH has become a mentor, advocate, educator, counsellor, and emotional anchor for people navigating the most tender chapters of their lives.Founded on Experience, Built on CompassionHer Helping Habit began when its founder, Katie—deeply familiar with both clinical and emotional aspects of fertility—recognized the urgent need for a safer, more transparent, relationship-oriented model of fertility support.Together with Sarah and Emily, she built a team skilled in:Ethical practices Trauma-sensitive care Diverse therapeutic modalities Human development Transparent communication Donor and surrogate mentorship Their united mission: To transform family-building by honouring relationships, empowering informed consent, and supporting each individual with compassion and expertise.Global Reach, Local HeartWhile headquartered in Canada, Her Helping Habit works remotely with clients worldwide, ensuring that aspiring parents across continents have access to informed, ethical, transparent fertility support.As demand for relationship-centered fertility services grows, Her Helping Habit continues to expand its donor programs, surrogacy opportunities, embryo adoption pathways, and specialized consulting services.Clients can now explore:Egg Donation (Known Donation Model) Embryo Donation & Adoption Surrogacy Support & Matching Mexico Donor Program Parenthood Consulting Donor & Surrogate Education The HHH Fertility Frontier Channel — providing expert insights and compassionate educationA Mission That Inspires Global ChangeHHH’s vision extends beyond helping individual families. The organization aims to contribute to a global shift—one where fertility support becomes emotionally safer, ethically grounded, and human-centered for all.Its mission stands on five pillars:1. Open CommunicationEmpowering every participant to make informed choices that align with their values.2. Genuine ConnectionsEncouraging meaningful relationships that enrich the entire family-building journey.3. Ethical ExcellenceEnsuring transparency, fairness, integrity, and accountability at all stages.4. Family-Centric SupportNurturing every individual involved—intended parents, donors, surrogates, and children.5. Personalized JourneysHonouring the uniqueness of every story, every family, and every dream.Through these principles, Her Helping Habit continues to build bridges of understanding between donors, surrogates, and intended parents—fostering communities where families grow through love, connection, and shared purpose.About Her Helping HabitFounded in 2018, Her Helping Habit is a Canada-based fertility support organization specializing in known egg donor coordination, surrogacy matching, embryo donation, fertility consulting, and therapeutic counselling. With a holistic and trauma-informed approach, HHH helps clients build families while honouring relationships, emotional well-being, and ethical transparency. The HHH team supports clients across Canada and worldwide through virtual services.Book Your Free Consultation TodayHer Helping Habit offers a free 30-minute consultation for individuals and families exploring donor conception, surrogacy, fertility guidance, or emotional support.To schedule a consult or learn more, visit: https://herhelpinghabit.com Media Contact Organization: Her Helping Habit Contact Person: Her Helping Habit Website: https://www.herhelpinghabit.com Email: Send Email Country:Canada Release id:38996 The post Her Helping Habit Expands Its Mission to Transform Family-Building Through Ethical, Transparent, and Relationship-Centered Fertility Support appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.

Lawcris Unveils their MaterialHub – A Bold New Creative Space in Leeds

Leeds, United Kingdom, 12th Dec 2025 – Lawcris, a leading name in the supply of decorative panels and worktops, have launched their new MaterialHub. This inspiring new creative space designed exclusively for interior designers, architects, furniture makers and shop fitters.In a world dominated by AI and digital design, the MaterialHUB is a bold, physical space built to bring back hands-on creativity and real-world material exploration for interior designers and specifiers.The Lawcris MaterialHUB is a destination for imagination… with a twist. A train-themed creative hub that takes you on a journey through inspiration, materials, and innovation at every stop. Showcasing decorative panels from industry giants, the MaterialHUB is a tactile, trend-led destination, designed to empower the next generation of design thinking.Inside, visitors will find an unrivalled selection of swatch books, coaster-size samples, perfect for moodboards, A4 takeaways, and large-scale A3 and A2 displays to experience true scale. For those who want to see the bigger picture, full sheets are showcased in the adjoining warehouse, offering designers a rare opportunity to view entire patterns and textures in person.Lauren Barker, the person behind the design of the MaterialHUB, says, “The moment you walk in, your creative brain just explodes! The train theme is just the start… We’ve got actual suitcases made from decors, graffiti panels offering an urban underground edge, a control room with light displays and more inspiration than you can shake a swatch at. It’s a full-on designer playground packed with the latest trends and panel tech so you’ll never fall behind. You don’t just visit the MaterialHUB… you experience it!”Located in Leeds, the MaterialHub brings functionality, inspiration, and collaboration all together under one roof. This creative space is free to use and aims to help designers develop their ideas, connect with clients, and discover new materials in a fresh, engaging way.With free access, ample parking, superfast WiFi, and barista-style coffee on tap, the MaterialHUB has been designed as the ultimate resource for professionals shaping tomorrow’s interiors. Whether you’re selecting decors, building client presentations, or seeking trend inspiration, the MaterialHUB is your new creative home.Explore the Features of this Creative PlaygroundThe MaterialHub has been thoughtfully designed with a variety of purpose-built zones that cater to every stage of the creative process:Snack & Spec CafeA relaxed café-style area that offers free snacks and drinks stations and provides a welcoming environment for professionals to catch up with a colleague, sketch out ideas, or meet with new clients.The Control RoomA fully equipped boardroom space for presentations, client meetings, and video calls. Its professional, private and practical design is ideal for making a positive first impression.The Luggage LoungeAn informal, lounge area perfect for brainstorming sessions, team catch-ups, or casual client chats. Plus, professionals can take a break with ‘The Forgotten Case’, an escape-room-inspired team-building game that aims to spark creativity and boost problem-solving skills.Sample SwitchboardTheir Sample Switchboard hosts an extensive range of materials and finishes from top brands including Egger, Kronospan, Fundermax, Emporio Skin, and Hanex.Free to Use The MaterialHub is completely free to use and is open exclusively to interior designers, architects, and other creative professionals. To book this space, designers simply need to contact the Lawcris team.For more information or to arrange a visit, contact materialhub@lawcris.co.uk.About LawcrisLawcris is a leading UK-based supplier of premium wood-based panels and surface materials. Known for quality, service and innovation, they support interior designers and manufacturers with an extensive product portfolio and a customer-first approach. Media Contact Organization: Lawcris Contact Person: Matthew Hines Website: https://www.lawcris.co.uk/ Email: sales@lawcris.co.uk Contact Number: +441132177177 Address:Knowsthorpe Gate, Leeds, West Yorkshire, LS9 0NP City: Leeds Country:United Kingdom Release id:38997 The post Lawcris Unveils their MaterialHub – A Bold New Creative Space in Leeds appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.

Nomadic.Cool Unveils the World’s First Lightweight Compressor Cooler Backpack on Indiegogo

Nomadic.Cool announces the launch of the world’s first lightweight compressor-cooler backpack, engineered for backpackers, festival campers, bike-packing adventurers, and off-grid travellers. Weighing just 4 kg when empty, Nomadic.Cool offers truly portable cooling with a high-efficiency compressor system and an integrated 100Wh battery capable of up to 48 hours of performance. Now live on Indiegogo, the project brings a new era of mobility, convenience, and sustainability to outdoor exploration. The press release highlights the inspiration behind the invention, the product’s unique features, and the team’s mission to support global adventurers with reliable cooling anywhere in the world. Austria, 12th Dec 2025 - Nomadic.Cool, founded by visionary product innovator Heinz Szolarz, proudly unveils the world’s first lightweight compressor-cooler backpack — marking a groundbreaking advancement for backpackers, festival campers, bike-packing adventurers, and outdoor explorers. Weighing just 4 kg when empty, it delivers the first truly portable, off-grid cooling solution without the bulk or limitations of traditional coolers.Now live on Indiegogo, this next-generation cooling system solves one of the longest-standing challenges faced by outdoor enthusiasts — keeping drinks, food, and essential medication cool without compromising mobility, comfort, or sustainability.https://www.indiegogo.com/en/projects/heinzszolarz/nomadic-cool--2  A Revolutionary Cooling Solution for the New Generation of TravelersUnlike old-school bulky coolers and battery-draining electric boxes, Nomadic.Cool uses a smart, lightweight compressor cooling system that keeps contents chilled for hours — completely off-grid and solar compatible. Whether it's backpackers trekking mountain trails or festival campers dancing for 72 hours straight, this modern mobility cooler is the game-changer they’ve been waiting for.  Who It’s Designed ForNomadic.Cool is tailored for the needs of:Backpackers & lightweight campersFestival & event campersBike & road campersProduct FeaturesNomadic.Cool’s forward-thinking design includes:Smart compressor coolingSolar compatibilityLightweight ergonomic backpack designDurable insulated interiorHolds multiple cans/bottles with organized structure Battery & PerformanceNomadic.Cool features an integrated 100Wh high-efficiency battery, providing up to approximately 48 hours of cooling, depending on climate and usage conditions. When paired with a compact solar panel, adventurers can remain fully self-sufficient for extended periods — ideal for remote trails, multi-day festivals, and off-grid travel. Support the CampaignBackers can now support Nomadic.Cool on Indiegogo and become the first owners of the future of outdoor cooling technology:https://www.indiegogo.com/en/projects/heinzszolarz/nomadic-cool--2   Media Contact Organization: Nomadic Cool Contact Person: Heinz Szolarz Website: https://www.nomadic.cool/ Email: Send Email Contact Number: +4367763731023 Country:Austria Release id:38994 The post Nomadic.Cool Unveils the World’s First Lightweight Compressor Cooler Backpack on Indiegogo appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.

EcoModular Announces Intention to Pursue Direct Listing on NASDAQ

MARBELLA, Spain – 12th Dec 2025 – EcoModular, a next-generation volumetric modular manufacturing company, today announced its intention to pursue a Direct Listing on the NASDAQ Stock Market. This strategic move is designed to accelerate the company's mission to develop a global platform for AI-driven, sustainable modular manufacturing.The company is currently executing a comprehensive growth strategy focused on integrating robotics, automation, and digital-twin engineering to deliver residential, commercial, and infrastructure solutions at scale. Central to this expansion is the "MegaFactory" program, which aims to establish automated manufacturing hubs across Europe and North America. These facilities are engineered to utilize AI-driven design, predictive quality control, and circular materials to significantly reduce costs, compress build timelines, and lower carbon emissions.In parallel with its capital markets strategy, EcoModular is actively expanding into key international territories. The company is pursuing targeted acquisitions in Europe and the United States to bolster its manufacturing capacity. Furthermore, EcoModular is preparing to launch its Portugal Manufacturing & Residency Fund, a €50 million investment vehicle designed to anchor expansion into Southern Europe, Africa, and Brazil. This cross-border network prioritizes environmental responsibility and aims to address global infrastructure needs with high-performance modular buildings."We are scaling modular innovation into a global movement," said Edvinas Cinga, Founder and CEO of EcoModular. "Our platform combines advanced manufacturing, digital-twin intelligence, and sustainability into a unified ecosystem built for governments and developers. Pursuing a listing on NASDAQ reflects our operational maturity and positions EcoModular to become a next-generation industrial leader."About EcoModularEcoModular is a global modular construction innovator developing sustainable, AI-powered, and scalable solutions for modern housing and infrastructure. The company combines intelligent design, robotics, and renewable materials to accelerate the transition to next-generation smart building systems.Website: https://ecomodular.com/Forward-Looking Statements This release contains forward-looking statements regarding future plans, strategies, and listing timetables. These statements are subject to risks and uncertainties that could cause actual results to differ materially. EcoModular undertakes no obligation to update forward-looking statements except as required by law. Media Contact Organization: EcoModular Contact Person: Andrew Meyer Website: https://ecomodular.com/ Email: Send Email Contact Number: +35314370909 Address:Unit 518a Grants Crescent Address 2: Greenogue Business Park, Rathcoole City: Dublin State: DUBLIN Country:Ireland Release id:38933 The post EcoModular Announces Intention to Pursue Direct Listing on NASDAQ appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

SHENZHEN, CHINA - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.   With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.   Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.   The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.   More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.   The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.   On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.   About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.   About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.   CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.   CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.   Reference National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.   CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.   This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.     Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/

When Is Back Surgery the Right Choice? A Guide for Phoenix Patients

United States, 12th Dec 2025 - Back pain can range from mild discomfort to debilitating symptoms that affect every aspect of daily life. While many spinal conditions improve with rest, therapy, or other non-surgical treatments, there are circumstances where surgery becomes the most effective option. Knowing when to consider back surgery helps patients approach treatment decisions with clarity rather than fear.Back surgery is typically explored when pain is ongoing and resistant to conservative care. Patients who experience persistent discomfort for several months—despite physical therapy, medication, or injections—may have an underlying spinal condition that requires surgical correction. Structural issues such as disc herniation, spinal narrowing, or vertebral instability can continue to worsen without intervention, especially when nerve tissue is involved.Changes in nerve function are often a key sign that surgery may be necessary. Symptoms such as shooting pain, numbness, tingling, or weakness in the arms or legs suggest nerve compression within the spine. When these symptoms begin to progress or interfere with walking, grip strength, or balance, a spine specialist may recommend surgical evaluation to prevent long-term nerve damage.Lifestyle limitations are another important consideration. When back pain interrupts sleep, prevents work responsibilities, or makes everyday activities like sitting, standing, or walking difficult, it may be time to look beyond conservative care. Advances in spine surgery have made many procedures more precise and less invasive, allowing eligible patients to recover more quickly and return to normal activities sooner.A thorough diagnostic process is essential before surgery is ever recommended. Modern imaging and comprehensive evaluations help pinpoint the exact cause of pain so that treatment is targeted and appropriate. Surgery is only advised when there is a clear connection between a patient’s symptoms and a correctable spinal issue.For individuals in Phoenix seeking expert guidance, Dr. David Prior, Orthopedic Spine Surgeon, offers a thoughtful, individualized approach to spine care. By carefully assessing each patient’s condition and considering all available options, Dr. Prior helps patients determine whether surgery is necessary—and ensures it is pursued only when it offers the greatest opportunity for lasting relief and improved quality of life.Check out more information about Outpatient Spine Surgery, Spinal Fusion, Scottsdale Spine Surgeons, and Top Back Surgeons in Scottsdale. Follow us on Facebook and X.The text above is intended for general informational purposes only and should not be considered medical or legal advice. If you have any physical or emotional concerns, contact your doctor for proper consultation. Media Contact Organization: Dr. David Prior Contact Person: Office Manager Website: https://phoenixbacksurgeon.com Email: Send Email Country:United States Release id:38986 The post When Is Back Surgery the Right Choice? A Guide for Phoenix Patients appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.